Jeffrey Scott Cole - Apr 2, 2024 Form 4 Insider Report for Cadrenal Therapeutics, Inc. (CVKD)

Role
Chief Operating Officer
Signature
/s/ Matthew K. Szot, Attorney-in-fact
Stock symbol
CVKD
Transactions as of
Apr 2, 2024
Transactions value $
$0
Form type
4
Date filed
4/3/2024, 05:21 PM
Previous filing
Apr 3, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CVKD Stock Options Award $0 +150K $0.00 150K Apr 2, 2024 Common Stock 150K $0.62 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of options to purchase 150,000 shares of common stock, which shall vest 1/4 on April 1, 2025 and thereafter pro rata on a monthly basis over three years, subject to the Reporting Person's continued service to the Issuer through each vesting date, having an exercise price equal to the fair market value of the Issuer's common stock on the effective date of the grant.